Posts

A combined preclinical therapy of cannabinoids and temozolomide against glioma.

Authors: Sofía Torres, Mar Lorente, Fátima Rodríguez-Fornés, Sonia Hernández-Tiedra, et al
Molecular Cancer Therapeutics, January 2011

Glioblastoma multiforme (GBM) is highly resistant to current anticancer treatments, which makes it crucial to find new therapeutic strategies aimed at improving the poor prognosis of patients suffering from this disease. Δ(9)-Tetrahydrocannabinol (THC), the major active ingred…

Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.

Authors: Zahida Qamri, Anju Preet, Mohd W. Nasser, Caroline E. Bass, Gustavo Leone, et al
Molecular Cancer Therapeutics, November 2009

Cannabinoids have been reported to possess antitumorogenic activity. Not much is known, however, about the effects and mechanism of action of synthetic nonpsychotic cannabinoids on breast cancer growth and metastasis. We have shown that the cannabinoid receptors CB1 and CB2 ar…

Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.

Authors: Alessia Ligresti, Aniello Schiano Moriello, Katarzyna Starowicz, Isabel Matias, et al
Journal of Pharmacology and Experimental Therapeutics, September 2006

Delta(9)-Tetrahydrocannabinol (THC) exhibits antitumor effects on various cancer cell types, but its use in chemotherapy is limited by its psychotropic activity. We investigated the antitumor activities of other plant cannabinoids, i.e., cannabidiol, cannabigerol, cannabichrom…

Fatty acid amide hydrolase deficiency limits early pregnancy events.

Authors: Haibin Wang, Huirong Xie, Yong Guo, Hao Zhang, Toshifumi Takahashi, et al
Journal of Clinical Investigation, August 2006

Synchronized preimplantation embryo development and passage through the oviduct into the uterus are prerequisites for implantation, dysregulation of which often leads to pregnancy failure in women. Cannabinoid/endocannabinoid signaling via cannabinoid receptor CB1 is known to…

Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling.

Authors: Sachin Patel and Cecilia J. Hillard
Journal of Pharmacology and Experimental Therapeutics, July 2006

Extracts of Cannabis sativa have been used for their calming and sedative effects for centuries. Recent developments in drug discovery have suggested that modulation of neuronal endogenous cannabinoid signaling systems could represent a novel approach to the treatment of anxie…

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

Authors: A.W. Zuardi, J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira, F.S. Guimarães
Brazilian journal of medical and biological research, April 2006

A high dose of delta9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of delta9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent whi…

The endocannabinoid-CB(1) receptor system in pre- and postnatal life.

Authors: Ester Fride
European Journal of Pharmacology, October 2004

Recent research suggests that the endogenous cannabinoids (“endocannabinoids”) and their cannabinoid receptors have a major influence during pre- and postnatal development. First, high levels of the endocannaboid anandamide and cannabinoid receptors are present in the preimpla…

Two hundred and thirteen cases of marijuana toxicoses in dogs.

Authors: Pawel Janczyk, Caroline W Donaldson, Sharon M. Gwaltney
Veterinary and Human Toxicology, February 2004

Marijuana (Cannabis sativa) is a commonly used recreational drug among humans; animals may be exposed following ingestion or accidental inhalation of smoke. From January 1998 to January 2002, 213 incidences were recorded of dogs that developed clinical signs following oral exp…

The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy.

Authors: Melisa J. Wallace, Robert E. Blair, Katherine W. Falenski, Billy R. Martin, Robert J. DeLorenzo
Journal of Pharmacology and Experimental Therapeutics, October 2003

Several lines of evidence suggest that cannabinoid compounds are anticonvulsant. However, the anticonvulsant potential of cannabinoids and, moreover, the role of the endogenous cannabinoid system in regulating seizure activity has not been tested in an in vivo model of epileps…

Cannabinoid receptor localization in brain.

Authors: M Herkenham, A B Lynn, M D Little, M R Johnson, L S Melvin, B R de Costa, K C Rice
Proceedings of the National Academy of Sciences, March 1990

[3H]CP 55,940, a radiolabeled synthetic cannabinoid, which is 10-100 times more potent in vivo than delta 9-tetrahydrocannabinol, was used to characterize and localize a specific cannabinoid receptor in brain sections. The potencies of a series of natural and synthetic cannabi…

Pharmacokinetics of cannabidiol in dogs.

Authors: E Samara, M Bialer, R Mechoulam
Drug Metabolism and Disposition: The Biological Fate of Chemicals, May/June 1988

Cannabidiol (CBD) is one of the major nonpsychoactive cannabinoids produced by Cannabis sativa L. Recent studies have shown that CBD has a high protective index, comparable to that of phenobarbital and phenytoin. Because CBD has been reported to possess both anticonvulsant and…

Pharmacokinetics of delta9-tetrahydrocannabinol in dogs.

Authors: Edward R. Garrett, Edward R. Garrett, C. Anthony Hunt
Journal of Pharmaceutical Sciences, March 1977

The pharmacokinetics of intravenously administered 14C-delta9-tetrahydrocannabinol and derived radiolabeled metabolites were studied in three dogs at two doses each at 0.1 or 0.5 and 2.0 mg/kg. Two dogs were biliary cannulated; total bile was collected in one and sampled in th…